EOLS
Evolus, Inc.
Key Financials
Operating Income
$-32662000
↑ 5.1%
Net Income
$-51641000
↓ 2.4%
Gross Profit
$197.1M
↑ 8.1%
Revenue
$297.2M
↑ 11.6%
Total Liabilities
$249.0M
↑ 9.7%
Shareholders' Equity
$-23106000.00
↓ 518.4%
EPS (Diluted)
$-0.80
↑ 1.2%
Cash & Equivalents
$53.8M
↓ 38.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| EFFECT | 6/12/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| S-3 | 6/5/2026 | View on SEC |
| 10-Q | 5/4/2026 | View on SEC |
| 8-K | 5/4/2026 | View on SEC |
| DEFA14A | 4/29/2026 | View on SEC |
| DEF 14A | 4/29/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EOLS |
| Company Name | Evolus, Inc. |
| CIK | 1570562 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (949) 284-4555 |